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Introduction
The concept of carrying a cytotoxic radionuclide directly 
to cancerous cells is an attractive alternative to conventional 
forms of radiation treatment. The very close contact between the 
radionuclide and the cell to be destroyed enables the absorbed 
radiation to be concentrated at the site of abnormality with 
the minimal injury to healthy tissue.1 The concept is not new. 
After a stalemate period in which radiometabolic treatment 
seemed to be unfashionable, not only has the already-existing 
radionuclide therapy returned to be appreciated and widely 
applied, but novel radionuclide therapies have also come about 
in recent years. In fact, the European Association of Nuclear 
Medicine (EANM) has published guidelines for the planning and 
actuating of most of these therapies. Prospects are excellent and 
they will revolutionise treatment of some common diseases as 
their use has been proven in studies and an increasing number 
centres are applying these treatments all over Europe, even as 
first-line. This article is a representative overview regarding the 
current common radionuclide therapy applications and the new 
radionuclide treatments available.
Basic principles and considerations
Several factors affect uptake of radiopharmaceuticals into 
diseased tissue, e.g. variations in interstitial pressure and in 
blood perfusion. The cumulative absorbed radiation close to 
tissue undergoing radionuclide therapy is a function of both the 
quantity of radiopharmaceutical taken up at a cellular site and 
its subsequent retention at that site.2 The physical half-life must 
not be too short since the radionuclide irradiates diseased tissue 
insufficiently. A long half-life gives unnecessary protracted doses 
to normal tissue. No radiopharmaceutical is entirely selective. 
Radiation toxicity assessments are required. Radionuclides may 
be classified into five groups according to the range of principal 
radiation emitted: alpha, beta with a mean range less than 200 
µm, beta with a mean range of more than 200 µm, beta with 
a range greater than 1 mm, and radionuclides which decay by 
processes called electron capture and/or internal conversion.3 
Size of tumour masses, potential inhomogeneity of uptake of 
the radiopharmaceuticals, availability and costs all affect the 
choice of a radionuclide label. 
Thyroid radionuclide therapy
Perhaps the best-known application of radionuclide therapy 
is the use of radioiodine (131I) in malignant and benign thyroid 
disease. The Royal College of Physicians has recently updated 
guidelines issued in 1995 with the latest recommendations for 
the management of hyperthyroidism. Radioiodine therapy is 
the treatment of choice in patients with Plummer’s disease 
provided there is no sign of malignancy. Surgery is being used 
less frequently in Graves’ disease and the preferred treatment 
is now 131I. Age is not a limit in such cases because low doses are 
administered, and considered quite safe. Radio-iodine therapy 
or surgery are indicated when a goitre causes local symptoms 
(dyspnoea, dysphagia) but therapy is preferred in elderly 
patients with concomitant diseases or patients with recurrence 
post-surgery.4 
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For more than 50 years, radioiodine has also been used in 
treatment of thyroid malignancy. Good results with respect 
to overall and recurrence-free survival in patients with well-
differentiated thyroid carcinoma confirm the efficiency of their 
safe treatment as follows:4 
1.  Allows detection of metastases not detectable by standard 
imaging
2.  Prophylactic ablation of thyroid remnants after near-total 
thyroidectomy
3.  Successfully indicated in local recurrences, lymph nodes 
or distant metastases where tumour burden is low.
Myeloproliferative disease
Phosphorous-32 (32P) was the first therapeutic radioisotope 
used in leukaemia about 70 years ago. Today there remains a 
distinct subgroup of elderly patients with polycythaemia vera 
and essential thrombocythaemia who can be treated with 
oral or intravenous 32P. Since the range of beta emissions is 
at most a few millimetres, and since 32P emits no other types 
of radiation, no hospital admission is required. It has been an 
accepted treatment for myeloproliferative disease for more than 
30 years.5 32P is incorporated into the nucleic acids of rapidly 
proliferating cells and suppresses hyperproliferative cell lines 
rather than eradicate them. It is perfectly well tolerated in the 
elderly (>65 years) and induces a long survival with an excellent 
quality of life.5 Patients should be pre-treated with venesection 
to reduce haematocrit to 42-47%. One must note that 32P in 
young and middle-aged increases risk of leukaemia several 
years after therapy, therefore other alternatives are considered 
such as hydroxyurea and anagrelide since they are considered 
a safer first-line treatment and can be administered on a long 
term basis too.6,7 
Palliation of metastatic bone disease
Pain associated with bone metastases is a clinical problem 
contributing to patient morbidity, reducing quality of life 
and bringing about depression, anxiety, fear and loss of 
independence.8 Symptoms are exacerbated by neurologic 
deficits, pathologic fractures, immobility and sequelae of 
hypercalcaemia.9 Three palliative therapies for metastatic bone 
pain provide symptom control:
1. External beam radiotherapy
2. Narcotic and non-narcotic analgesics and
3. The introduction of radioactive bone seeking 
biphosphonates into the management plan.
There is now compelling data to support the use of bone-
seeking radiopharmaceuticals as effective (in 90%) and cost-
effective in pain palliation.10 Almost any cancer may metastasize 
to bone, and may be a significant symptom in more than 50% of 
the most common cancers. Bone-seeking qualities of strontium 
(Sr) were described by Stöltzner in 1874 and the isotope 89Sr was 
first reported in 1937. 89Sr started being used in clinical practice 
for metastatic bone disease in 1941, but only in the 1980s was 
the potential of this therapy fully recognised. Beta-emitting 
89Sr, 32P, samarium(153Sm)-ethylenediaminetetramethylene-
phosphate and rhenium(186Re)-hydroxyethylidene are 
approved for use in many regulatory jurisdictions. Nuclear 
medicine physicians should now be involved in long term 
patient care and should collaborate with referring physicians 
in multi-disciplinary clinics. They should also be involved 
as early as possible for optimum results. Indications for 
radiopharmaceutic therapy in patients with bone metastases 
symptoms are listed in table 1 and contra-indications in Table 
2. Distribution of these radiopharmaceuticals is predicted from 
99Tc-methylene-diphophonate bone scan, also a bone seeking 
radiopharmaceutical and routinely carried out in nuclear 
medicine departments. External beam techniques have the 
advantage of more rapid palliation, but unsealed source therapy 
agents offer a more sustained radiotherapy besides treating 
more than one metastatic site concomitantly. The most recent 
advancement is the use of the alpha-emitting radium-223 (Ra), 
which seems a promising new treatment.11 A multi-centre trial 
of prostate cancer patients demonstrated that 223Ra is at least 
as effective as currently used radiopharmaceuticals and is also 
considerably less toxic. By contrast to beta-emitting isotopes, 
alpha-emitters produce a high linear-energy-transfer radiation 
and increases anti-tumour effect by virtue of its densely ionizing 
abilities locally but with relative sparing of the bone marrow 
because of its short-track length.
Hepatic cell carcinoma (HCC)
HCC is one of the most common cancers worldwide and is 
increasing due to better healthcare of liver cirrhosis and chronic 
hepatitis C patients. Prognosis is extremely poor. Curative 
treatment (liver transplantation, surgical resection, ethanol 
injection, radiofrequency ablation) can only be carried out in 
less than 25% of patients. Systemic chemotherapy leads only to 
low levels of response without any improvement in survival.12 
External radiotherapy is of little use because of the high risk of 
hepatic toxicity. Thus, two principle therapeutic approaches 
may be considered: arterial chemoembolization (causes 
tumour ischaemia) and metabolic radiation therapy via arterial 
administration. HCC is a hypervascularised tumour mainly 
supplied by the hepatic artery. Non-tumoral liver is mostly 
vascularised by the portal vein. Hence intra-arterial injection 
of radioactive therapeutic agent and its trapping in tumour 
micro-vessels enables a high tumour:non-tumour liver ratio 
to be attained, with maximum delivery of high dose to tumour. 
Beta-emitting 131I-lipiodol (ethiolised oil, a naturally iodinated 
fatty acid ethyl ester of poppy seed oil), rhenium(188Re)-lipiodol 
and yttrium(90Y)-labelled microspheres are applied. The first 
attempts to use 131I-lipiodol therapy in HCC dates back to 1986. A 
partial or incomplete response rate (i.e. reduction of more than 
50% in tumour size or tumour marker amount) is observed in 
an average of 40%,13 even up to 71% in some studies. 131I-lipiodol 
has proven effectiveness in the treatment of HCC with portal 
thrombosis, and as adjunct treatment for operated HCC in which 
it reduces the risk of recurrence. This treatment is at least as 
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effective as chemoembolisation but is much better tolerated. 
This treatment involves the nuclear physician and radiologists 
who intervene under fluoroscopic control.
Radiosynovectomy
An overview of most studies investigating therapeutic 
radionuclides and their direct injection into joints affected by 
synovitis do not show a considerable therapeutic gain when 
administered alone, but combining long-acting steroids with 
them has synergistic effects.14 Benefits are observed in 60-
80% of patients with a large range of refractory and painful 
arthropathies (e.g. rheumatoid arthritis, spondyloarthropathies 
such as psoriatic arthritis, persistent synovial effusions, other 
inflammatory joint diseases such as Lyme’s and Bechet’s 
disease).15 The beta emitters 90Y-citrate/silicate (knee), 186Re-
sulphide (hips, shoulders, elbows wrists, ankles, subtalar 
joints) and erbium(169Er)-citrate (metacarpophalangeal, 
metatarsophalangeal, digital interphalangeal joints) are all 
approved in Europe.15 Collaboration between rheumatologists, 
orthopaedic surgeons and nuclear physicians is required. 
Together they must weigh risks against benefits. Radiation 
in non-malignant conditions should be resorted to when all 
other treatments are unsuccessful. Patients must fail at least 
one intra-articular injection of long-term glucocorticoids. 
The mechanism of action of these radionuclides is probably 
coagulation necrosis of superficial synovial cells due to beta 
irradiation, and their consequent sloughing. Contra-indications 
include patients with symptoms due exclusively to cartilage 
damage and ruptured Baker’s cyst. Treatment can be repeated 
after 6 months. Response is unlikely before 14 days, and may 
be delayed even up to 1 month. 
Metaiodobenzylguanidine (MIBG) therapy
Since 1981 radioiodinated MIBG has established its place 
in diagnosis and treatment of tumours derived from the neural 
crest, and which uptake and retain this radiopharmaceutical. 
The higher sensitivities and specificity of MIBG scintigraphy in 
phaeochromocytoma and neuroblastoma led to its therapeutic 
use in these conditions.16 Over 95% of phaeochromocytomas 
concentrate MIBG and this therapy has proven to reduce 
tumour function, allow symptom palliation, tumour arrest and 
regression. 131I-MIBG also has a proven value in the treatment 
of stage III or IV neuroblastomas and paragangliomas. Studies 
demonstrate that this therapy should be incorporated earlier 
and at a more favourable moment in treatment protocols, even 
instead of combination chemotherapy to obtain operability.16 
Several new applications are being investigated with the aim 
of improving the therapeutic index. 131I-MIBG is probably the 
best palliative treatment for patients with advanced disease, as 
the invasiveness and toxicity of this therapy compare favourably 
with that of chemotherapy, external beam radiotherapy and 
immunotherapy.17 In carcinoid tumour and medullary thyroid 
carcinoma the sensitivities are slightly lower and fewer patients 
with these conditions undergo this therapy successfully.
Radioimmunotherapy (RIT) in 
non-Hodgkin’s lymphoma (NHL) treatment
RIT represents an exciting new therapeutic option for the 
treatment of B-cell NHL. Targeted radiotherapy is advantageous 
compared to other systemic therapies because chemotherapeutic 
agents have low selectivity whereas ligand-targeted radiotherapy 
is based on over-expression or potentially unique expression of 
target molecules on tumour cells. 
With the approval of two radiolabelled immunoconjugates, 
90Y-ibritumomab-tiuxetan and 131I-tositumomab, RIT is 
emerging as a safe and effective treatment strategy. RIT 
provides a novel approach in which monoclonal antibodies 
directed against tumour-specific antigens are used to target 
therapeutic radioisotopes to sites of disseminated disease.18 
Toxicity to uninvolved tissues is minimised. NHL is inherently 
radiosensitive. Radiolysis is induced in both the target cell and 
adjacent tumour cells, because of radiation crossfire effect. 
Most B-cell lymphomas express CD20, making it a 
suitable target antigen for therapeutic radioactive monoclonal 
antibodies. CD20 is not present on stem cells and its expression 
Table 1: Most common indications for radionuclide 
therapy in patients with  bone metastases 
(McEwen AJ, 1996)
• Metastatic bone disease
• Positive bone scan irrespective of x-rays
• Bone pain
• Recurrent bone pain in previously irradiated site
• Pain in more than one site requiring analgesia
• Bone pain requiring radiotherapy to most painful site
• Radiotherapy to one site with multiple abnormalities   
on bone scan but no pain outside radiotherapy field
Table 2: Contraindications to radiopharmaceutical 
therapy in cancer patients with bone metastases 
(McEwan AJ, 1996)
• Platelet Count < 100,000  (relative)
• Platelet count < 60,000 (absolute)
• White count < 2.5 x 106/L
• Rapidly falling blood counts
• Evidence of disseminated intravascular coagulopathy
• Impeding pathologic fracture (treat acute symptoms 
and reconsider)
• Impeding cord compression (treat acute symptoms 
and reconsider)
• < 2 months projected survival
• Prior myelosuppressive chemotherapy
• Extensive soft tissue metastases
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does not vary at different stages of the cell cycle. Moreover, it 
does not internalise or shed from the cell surface in response to 
antibody binding. By linking anti-CD20 monoclonal antibodies 
to an appropriate therapeutic isotope (beta-emitters 131I and 
90Y), sites of disseminated disease can effectively be targeted. 
90Y-ibritumomab tiuxetan is a murine anti-CD20 monoclonal 
antibody linked via ‘tiuxetan’ to 90Y. The principle toxicity 
is reversible myelosuppression but is generally very well 
tolerated. The development of human anti-murine antibody 
(HAMA) reactions could potentially preclude re-treatment 
upon relapse but extensive studies have shown that incidence 
of HAMA reactions is only 1%.18 A 90Y-ibritumomab-tiuxetan 
regimen is completed in 1 week with 2 hospital visits. An initial 
intravenous infusion of rituximab monoclonal antibody is given 
(250mg/m2). One week later, patients receive a second infusion 
of rituximab followed 4 hours later by a single injection of 90Y. 
Doses of radiation absorbed by uninvolved organs and marrow 
are well below acceptable safety levels.19 As the path-length of 
beta particles is very short, treated patients pose a negligible 
risk of irradiating other individuals (hospital workers, family 
members) and may be administered on an outpatient basis. RIT 
approach allows multiple sites of disseminated disease to be 
targeted simultaneously without having to identify the location 
of individual tumours. Major clinical studies have shown that 
RIT as second line therapy in NHL gives high response rates, 
increasing survival rate and reducing relapse rates or increasing 
time intervals between relapses. Today these encouraging 
results are pushing researchers to investigate the possibility of 
including 90Y-ibritumomab-tiuxetan earlier in NHL therapy, 
i.e. first-line. 
Receptor-targeted radiopeptide therapy
Peptides are important regulators of various biological 
processes. Radioactive neuropeptides like somatostatin 
analogues are widely used for symptomatic treatment of 
malignant hormone-secreting neuroendocrine tumours and 
their metastases. They act via high-affinity G-protein coupled 
receptors. The basis of somatostatin receptor-targeted 
radiotherapy is the over-expression of some of these receptor 
subtypes on neuroendocrine tumours and even some non-
neuroendocrine tumours. They inhibit hormone secretion 
and improve quality of life, with little effect on tumour size or 
growth. Neuroendocrine tumours often cause symptoms from 
excess hormone secretion rather than from growth, invasion 
or local anatomic effects. Frequently slow growing, they may 
still be life threatening. Many gastroenteropancreatic tumours 
including insulinomas, gastrinomas, vipomas, glucagonomas, 
somatostatinomas, and non-functioning pancreatic tumours 
are treated by these methods.
In diagnosis, the prototypic radioligand and the gold-
standard for somatostatin receptors scintigraphy,20 a routine 
scan in many nuclear medicine units, is 111-indium (111In)-
octreotide (somatostatin analogue). It is very sensitive and a 
preferred method in staging and follow-up of neuroendocrine 
tumours. Moreover, radiopeptides show rapid diffusion and 
localisation, rapid clearance, efficient laboratory synthesis 
and lack of immunogenicity. A remarkable response rate 
(stabilization and improved quality of life) in different cancers 
has been observed in major studies in many centres.20 In 
therapy, beta-emitter 90Y is most commonly used. Recently 
lutetium-177 (177Lu) has been introduced, allowing formation 
of a radiopharmaceutical with a sevenfold higher affinity 
to somatostatin type 2 receptors. 177Lu allows concomitant 
imaging and therapy. Chemical combination of a radionuclide 
with selective radiopharmaceutical is often complex since 
direct labelling is rarely possible. A large conjugating molecule 
(chelator) needs to be attached to the radiopharmaceutical 
to form kinetically and thermodynamically stable radiometal 
complexes. 
A sufficiently high expression of somatostatin receptors (by 
111In-octreotide scan) of all lesions demonstrated anatomically 
by conventional radiological techniques is required. The 
radiopharmaceutical concentration on scintigraphy should 
be at least as high as the non-specific uptake within the liver. 
Studies are underway to determine maximum doses that 
may be administered, and time intervals between repeated 
treatments. Although in it infancy, the concept of this therapy 
has been proven and is now being practiced in many European 
centres. Renal toxicity has been the main dose-limiting toxicity. 
Infusion of cationic amino acids reduces the uptake of peptides 
in tubular cells. Structural modifications of peptides will lead to 
new radiopeptides with much lower renal uptake. Somatostatin-
based radiopeptides with a more suitable receptor subtype 
profile will allow the targeting of a broader spectrum of tumours. 
Several new radiopeptides are under development. 
Conclusion 
Nuclear medicine is an ever-expanding speciality and this is 
not only true for diagnostic procedures, but also for radionuclide 
therapy. The aim of radionuclide therapy is to reach maximal 
radiation dose to the tumour or target-pathology, but only 
minimal dose to normal tissue. It may be tailored to the lesion or 
patient to be treated. Use of radiopharmaceuticals is becoming 
more widespread and popular since costs are decreasing rapidly 
and the implementation of such treatment is quite simple and 
straightforward. Today radionuclide therapy is mainly an 
integral part of nuclear medicine. In the future it will be part of 
a multi-disciplinary therapy. 
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